EPS for Auris Medical Holding AG (EARS) Expected At $

EPS for Auris Medical Holding AG (EARS) Expected At $

Auris Medical Holding AG (EARS) closed its day with loss -48.17% and ended at the price of $0.43.

Looking forward, for the quarter ending Dec-17, 1 analyst has a mean sales target of 0.00 million. It sustained ROA (TTM) at -76.00%.

The stock now shows its YTD (Year to Date) performance of -60.04 percent, whereas its Weekly performance stands at -48.48%. For every criteria that is met the company is given one point, if it is not met, then no points are awarded.

"The good news is really that we have. exciting data in the subgroup of patients who are most in need of a treatment", Meyer added. Auris Medical said it will terminate early the second trial, ASSENT (NCT02809118), a 300-patient study whose design was similar to the 256-patient HEALOS, except that it was created to measure improvement 91 days after treatment. The Altman Z-score depends on five financial ratios that can be calculated from data found on a company's annual 10K report.

The Relative Strength Index (RSI), developed by J. Welles Wilder, is a momentum oscillator that calculates the speed and change of price movements.

More news: Instagram Now Lets You Draw on Your Friends' Photos

Auris Medical has lurched from a failed late-stage study of its experimental tinnitus drug previous year to a Phase III flop for its hearing loss therapy. Usually the RSI is considered overbought when above 70 and oversold when less than 30. Bellevue Asset Management AG is the second biggest holder with 2 million shares now valued at 1.64 million whilst Zuercher Kantonalbank has 2 million shares valued at 2.32 million.

Auris Medical said at the time that Keyzilen also generated more positive results in the subgroup of patients suffering from tinnitus following otitis media, where Keyzilen treatment generated a clinically meaningful and statistically significant reduction of 14.8 points in TFI from baseline, versus 6.2 points for placebo. Whereas 0 of them predict the stock is a hold.

The company's Average Revenue Estimate for the current quarter is $0, while Low and High Revenue Estimates are $0 and $0 respectively.

Profitability analysis greatly helps in making investment decision.

At the end of 09/30/2017 reporting period, 4 institutional holders increased their position in Auris Medical Holding AG (NASDAQ:EARS) by some 197,646 shares, 11 decreased positions by 1,181,722 and 7 held positions by 10,219,262. Beta factor was calculated at 0. The monthly stock performance comes in at -2.09%. The stock boasts a consensus analyst "Buy" rating with the consensus recommendation standing at 2.00.